Microcap Ledger InspireMD, Inc. $NSPR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Miami, FL
- Fiscal year end
- December 31
- Shares outstanding
- 46,489,118 [10-Q 2026-08-14]
What the company doesAI summary of filing
InspireMD develops and commercializes medical devices for treating carotid artery disease and other vascular conditions, using proprietary MicroNet mesh technology integrated into carotid stents. The company generates revenue primarily from two commercial products: CGuard EPS, which is marketed in over 30 countries outside the U.S. through distributors, and CGuard Prime, which received FDA approval in June 2025 and is marketed in the U.S. through a direct salesforce. The company is also developing additional products, including SwitchGuard neuroprotection system and exploring applications for acute ischemic stroke treatment. InspireMD is in the revenue-generating stage, having launched CGuard EPS commercially in 2015 and recently launched CGuard Prime in the U.S. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $5.17M | −$28.01M | −$23.23M | $15.15M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $8.98M | −$48.79M | −$35.10M | $8.94M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $7.01M | −$32.01M | −$21.87M | $18.92M | [10-K 2026-03-18] |
- Quarterly cash burn
- −$11.62M
- Cash runway Estimate
- ~3.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 26,083,763 | [10-Q 2024-11-12] |
| 2025-03-12 | 29,689,857 | [10-K 2025-03-12] |
| 2025-05-08 | 30,635,346 | [10-Q 2025-05-08] |
| 2025-08-04 | 41,720,662 | [10-Q 2025-08-04] |
| 2025-11-10 | 42,370,995 | [10-Q 2025-11-10] |
| 2026-03-18 | 46,801,561 | [10-K 2026-03-18] |
| 2026-05-07 | 46,838,962 | [10-Q 2026-05-07] |
| 2026-08-14 | 46,489,118 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2025-08-06; declared effective 2025-08-14 [S-3 2025-08-06]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-23. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-23] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-27 | Stuka Paul | buy | 20,000 | $0.88 | [4 2026-05-29] |
| 2026-05-19 | Gleason Shane Thomas | sell | 22,778 | $1.01 | [4 2026-05-21] |
| 2026-05-14 | Stuka Paul | buy | 5,000 | $1.15 | [4 2026-05-15] |
| 2026-05-13 | Stuka Paul | buy | 10,000 | $1.16 | [4 2026-05-15] |
| 2026-05-12 | Slosman Marvin | buy | 21,000 | $1.20 | [4 2026-05-13] |
| 2026-05-11 | Stuka Paul | buy | 10,000 | $1.19 | [4 2026-05-12] |
| 2026-05-08 | Stuka Paul | buy | 65,626 | $1.16 | [4 2026-05-12] |
| 2026-02-02 | Gleason Shane Thomas | sell | 2,941 | $1.59 | [4 2026-05-21] |
| 2025-05-30 | Gleason Shane Thomas | sell | 7,186 | $2.51 | [4 2026-05-21] |
| 2025-05-29 | Gleason Shane Thomas | sell | 3,760 | $2.51 | [4 2026-05-21] |
| 2025-05-27 | Gleason Shane Thomas | sell | 1,572 | $2.51 | [4 2026-05-21] |
| 2025-05-23 | Gleason Shane Thomas | sell | 2,482 | $2.51 | [4 2026-05-21] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-21 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-08-17 | 8-K | Results of operations |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-29 | 8-K | Director or officer change |
| 2026-07-23 | 8-K | Listing notice or transfer |
| 2026-07-02 | 8-K | Director or officer change |
| 2026-06-11 | 8-K | Regulation FD disclosure |
| 2026-06-03 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-22 | 8-K | Director or officer change |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
Alerts for $NSPR
Email me when InspireMD, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.